News: Pfizer Inc (PFE.N)
27.85USD
11:45am EDT
$0.07 (+0.25%)
$27.78
$27.67
$27.88
$27.42
4,243,703
11,800,771
$31.14
$22.16
US STOCKS-Futures point to flat open before factory data
* Fed's Dudley to speak about national economic conditions
US STOCKS-Futures higher as positive momentum persists
* Fed's Dudley to speak about national economic conditions
US STOCKS-Futures higher as positive momentum persists
NEW YORK, July 2 - U.S. stock index futures rose modestly on Tuesday, indicating positive market momentum would continue as investors remain more comfortable with the economic outlook.
Pfizer, Novartis may join Amgen in bidding for Onyx: sources
NEW YORK - Onyx Pharmaceuticals Inc , whose cancer drugs promise a strong revenue stream, is attracting preliminary buyout interest from several large pharmaceutical companies such as Pfizer Inc and Novartis AG , two people familiar with the matter said on Monday.
Release of Eliquis blood clot preventer story
The blood clot preventer Eliquis, sold by Pfizer Inc and Bristol-Myers Squibb Co, proved as effective as widely used warfarin in treating a dangerous condition known as venous thromboembolism and caused far less bleeding, according to data from a large clinical trial.
Pfizer says shareholders snap up remaining Zoetis shares
- Pfizer Inc on Monday said it would complete the spinoff of its Zoetis Inc animal health business after investors offered to trade their Pfizer shares for the company's remaining majority stake in the unit.
UPDATE 2-Pfizer says shareholders snap up remaining Zoetis shares
June 24 - Pfizer Inc on Monday said it would complete the spinoff of its Zoetis Inc animal health business after investors offered to trade their Pfizer shares for the company's remaining majority stake in the unit.
Pfizer says shareholders snap up remaining Zoetis shares
June 24 - Pfizer Inc said on Monday that enough Pfizer shareholders offered to trade their shares for stock in Pfizer's majority owned Zoetis Inc animal health business to allow Pfizer to complete its spinoff of the unit.
Teva, Sun Pharma to pay $2.15 billion to settle Pfizer patent suit
- Pfizer Inc said Teva Pharmaceuticals Industries Ltd and Sun Pharmaceutical Industries Ltd would pay $2.15 billion to settle a patent suit related to its acid-reflux drug.
UPDATE 2-Teva, Sun Pharma to pay $2.15 bln to settle Pfizer patent suit
* Teva to pay $1.8 bln, half this year and rest by Oct 2014
Press Releases
- Eliquis® (apixaban) Demonstrated Comparable Efficacy and Significantly Lower Rates of Major Bleeding in Patients Compared to Current Standard of Care for the Treatment of Acute Venous Thromboembolism
- Pfizer Declares 24-Cent Third-Quarter 2013 Dividend
- Pfizer Announces Final Results of Zoetis Exchange Offer
- Advil® Is the Official Pain Reliever of Tough Mudder® Bringing #ReliefinAction to “Probably the Toughest Event on the Planet”
- Nutrition - Pharma Stocks in the News: Embark Holdings, GNC, Vitamin Shoppe, Gilead Sciences, Pfizer
- FDA Reviews, Acquisitions, Dividends, and Drug Study Results Highlight Solid Growth for Major Drug Companies - Research Report on Pfizer, Johnson & Johnson, Zoetis, AbbVie, and Lilly
- Pfizer Invites Public To View And Listen To Webcast Of July 30 Conference Call With Analysts
- Zoetis Becomes Fully Independent With Acceptance of Pfizer Shares Tendered in Exchange Offer
- Pfizer Announces Preliminary Results of Zoetis Exchange Offer and Adjusts 2013 Financial Guidance(1) Solely to Reflect Impact of Exchange Offer
- Pfizer Announces FDA Acceptance for Review of Application to Expand Labeling for XELJANZ® (tofacitinib citrate) for Adults with Moderately to Severely Active Rheumatoid Arthritis to Include Inhibition of Progression of Stru
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
